Lyon: Shanghai Pharmaceuticals Holding (02607) target price raised to HK$15.2, rated "outperform"

Lyon released a research report stating that Shanghai Pharmaceuticals Holding (02607) is expected to achieve a revenue of 283.6 billion yuan in the fiscal year 2025, an increase of 3% year-on-year, and a net profit of 5.73 billion yuan, an increase of 25.7% year-on-year, which is in line with market expectations. Traditional Chinese medicine has always been the core driver of the company's production business, and the company will continue to prioritize the development of innovative drug research and development to drive growth. The bank has raised its target price from HK$14.2 to HK$15.2 and maintains a "outperform" rating.